Trial Profile
Sequential Phase I/II Trial of Oral Vorinostat in Combination With Erlotinib in Non-small-cell Lung Cancer Patients With Mutations at Epidermal Growth Factor Receptor With Disease Progression After Erlotinib Treatment
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 09 May 2022
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary) ; Vorinostat (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Acronyms TARZO
- 01 Dec 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 04 Apr 2008 Status changed from initiated to recruiting as reported by ClinicalTrials.gov
- 09 Aug 2007 New trial record.